A Problem Hidden Inside the Science
Medicine has always presented itself as objective, evidence-based, and universal. The assumption built into that presentation is that what works for one human being works for all human beings, that biology is biology, and that a drug tested in one group of people will perform the same way in every group. That assumption, repeated across decades of research, has turned out to be dangerously wrong.
The clinical triel system has a representation problem that researchers, regulators, and patient advocates have been confronting with increasing urgency. For most of modern medical history, the people enrolled in clinical trials have skewed heavily toward white men in certain age ranges, leaving enormous gaps in the data used to approve treatments that are then prescribed to everyone. Women, people of color, the elderly, people with disabilities, and patients from lower-income backgrounds have been systematically underrepresented in the research that shapes clinical practice worldwide.
This is not a minor technical detail. It is a fundamental flaw in how medical knowledge has been built, and it has real consequences for people whose bodies were never adequately studied. Understanding how this happened, what it has cost underrepresented communities, and what is being done to change it is essential for anyone who wants to think clearly about the state of modern medicine.
How Historical Exclusion Became the Norm
The underrepresentation of diverse populations in clinical research did not happen by accident. It was shaped by a combination of regulatory decisions, institutional biases, logistical barriers, and historical betrayals of trust that together created a research culture that defaulted to a narrow participant profile for decades.
For much of the twentieth century, women of childbearing age were formally excluded from early phase clinical trials out of concern for potential fetal harm. While the intention may have been protective, the practical effect was that drugs were approved without adequate safety and efficacy data in women, who make up half the population and who process medications differently than men due to differences in body composition, hormonal cycles, kidney function, and metabolism. It was not until 1993 that the FDA issued guidelines requiring the inclusion of women in clinical trials and the analysis of sex-based differences in trial data.
The history with racial and ethnic minorities is more troubling still. The Tuskegee Syphilis Study, conducted by the U.S. Public Health Service between 1932 and 1972, enrolled 399 Black men with syphilis and deliberately withheld effective treatment from them for decades in order to study the natural progression of the disease. When this was exposed, the damage to trust between the Black community and medical institutions was profound and lasting. That breach of trust did not disappear when the study ended. It became part of a lived cultural memory that shaped how generations of Black Americans viewed medical research, creating entirely rational reluctance to participate in clinical studies.
Beyond the historical trauma, practical barriers have also played a major role. Clinical trials have historically been conducted at large academic medical centers concentrated in major cities, making participation difficult or impossible for people without reliable transportation, flexible work schedules, or the financial ability to take time off. Language barriers, lack of culturally competent outreach, and trial protocols that do not accommodate the realities of participants’ lives have all contributed to a research ecosystem that was simply more accessible to some people than others.
What Underrepresentation Actually Costs
When a clinical trial enrolls a population that does not reflect the diversity of people who will eventually use the treatment being studied, the knowledge gaps that result are not hypothetical. They translate directly into worse health outcomes for the people who were left out of the research.
Pharmacogenomics, the study of how genetic variation affects drug response, has made increasingly clear that ancestry and ethnicity can meaningfully influence how a person metabolizes medication. Certain genetic variants that affect drug metabolism are distributed unevenly across populations. When trials are conducted predominantly in one ethnic group, optimal dosing guidance may not apply accurately to people from other backgrounds. Prescribing a drug at a dose calibrated to one population to someone from a different population is not a minor imprecision. It can mean the difference between a therapeutic effect and a dangerous one.
Cardiovascular disease, diabetes, hypertension, and certain cancers disproportionately affect Black, Hispanic, and Native American communities, yet these groups have been underrepresented in the trials designed to study treatments for exactly these conditions. The result is a cruel irony: the populations bearing the greatest disease burden have often had the least influence on the research meant to address that burden.
Women’s health has suffered similarly. For decades, the assumption that male physiology was the default human physiology led to female patients being undertreated, incorrectly dosed, or dismissed when they reported symptoms that had not been observed in predominantly male trial populations. Heart disease presents differently in women than in men, and for years those differences went unrecognized in clinical settings partly because the research literature was built on male data.
The FDA Steps In: Regulatory Change Takes Shape
Recognition of these failures has been building within regulatory and research institutions for years, and the pace of change has accelerated significantly in the past decade. The FDA has made diversity in clinical research a visible institutional priority, moving from general guidance toward more concrete requirements that sponsors must address in their trial designs.
In 2022, the FDA Omnibus Reform Act included provisions requiring sponsors of certain clinical trials to submit diversity action plans describing how they intend to enroll a participant population that reflects the demographics of people affected by the condition being studied. This was a meaningful shift from encouragement to accountability. Rather than simply urging companies to try harder, it built diversity planning into the formal regulatory submission process.
The FDA has also published updated guidance on collecting and reporting race and ethnicity data in clinical trials, pushing for standardized approaches that allow for meaningful analysis of how treatments perform across different groups. The agency has been clear that post-hoc diversity is not sufficient. Diverse enrollment must be planned from the beginning of a trial, not patched in at the end.
Community engagement has become a recognized component of responsible trial design. Researchers are increasingly expected to work with community organizations, faith institutions, and culturally trusted healthcare providers in order to reach populations that have historically been excluded. This kind of outreach requires genuine relationship-building over time, and it cannot be rushed or reduced to a marketing campaign.
What the Industry Is Actually Doing Differently
Beyond regulatory pressure, there has been a genuine shift in how pharmaceutical companies, academic research centers, and advocacy organizations are approaching the design and execution of clinical trials. Some of this change is driven by ethics, some by business considerations, and some by the growing recognition that non-diverse trial data creates scientific problems that undermine the value of the research itself.
Decentralized clinical trials have emerged as one of the most promising structural changes. Traditional trials required participants to travel to a central research site for every visit, a model that systematically excluded people with transportation barriers, demanding work schedules, or caregiving responsibilities. Decentralized models use telehealth visits, local healthcare providers, home nursing visits, and remote monitoring devices to bring the trial to the participant rather than requiring the participant to come to the trial. This does not eliminate all barriers, but it substantially reduces the logistical burden that has historically made participation impossible for many people.
Patient advocacy organizations representing specific communities have taken on more active roles in shaping trial design, pushing researchers to think through recruitment strategies, protocol burden, and participant support structures before a single person is enrolled. When the communities most affected by a disease have a voice in how research about that disease is conducted, the resulting trials tend to be more relevant, more inclusive, and ultimately more useful.
Pharmaceutical companies have also begun examining their own outreach practices with more honesty. Generic recruitment strategies posted in academic medical centers were never going to reach the full diversity of patients who needed access to research. Targeted community outreach, partnerships with federally qualified health centers, and investment in multilingual recruitment materials represent a more intentional approach to building trial populations that reflect the real world.
Trust Is Not Given Back Overnight
All of these structural and regulatory changes are necessary, but they are not sufficient on their own. The underrepresentation of certain communities in clinical research is not only a logistical problem. It is a trust problem rooted in real history, and trust cannot be rebuilt through policy memos alone.
For communities with deep and justified reasons to be skeptical of medical research, the path back to participation runs through sustained, honest, community-led engagement. It means researchers showing up before they need something, building relationships with community leaders without an enrollment agenda, and being transparent about who benefits from research and how participant data is used and protected.
It also means listening when communities articulate what they would need in order to feel safe participating, whether that is stronger privacy protections, more accessible trial sites, compensation that genuinely reflects the time and burden involved, or simply being treated as intelligent adults who can understand and evaluate the risks they are being asked to take.
The science of clinical research is only as good as the people it includes. A trial that produces results applicable to everyone requires participants who represent everyone. That goal is not idealistic. It is the basic standard that medical research should have been holding itself to all along, and getting there requires acknowledging clearly how far short the field has fallen.
